Onkologie. 2013:7(1):40-47

Cancers, health and economy - parts of Pandora´s box?

Edvard Geryk1, Petr Koška2, Teodor Horváth1, Václav Živec1
1 Fakultní nemocnice Brno
2 FN u sv. Anny v Brně

In 2008 (Globocan 2008; IARC), 12.663 million new cancer cases occurred worldwide and, of them, 2.445 million in the EU. Of 7.565 million global

cancer deaths, nearly 1.235 million cases were in the EU, and from five-year cancer prevalence estimates of 28.8 million worldwide, almost 6.617

million concerned the EU. The cancer prevalence statistics included: breast, 18 %; colorectum, 11%; prostate, 11 %; lungs, 6 %; stomach, 5.5 %;

cervix, 5.5 %; bladder, 4 %; uterus, 4 % round the world; and breast, 20 %; colorectum, 14 %; prostate, 18 %; lungs, 5 %; melanoma, 4 %; kidney,

3 %; uterus, 3 %; and NH lymphoma, 3 % in the EU. In 2030 the expected number can reach more than 21 million worldwide, 3 million in the EU

and 93,000 new cases in the Czech Republic (all sites ICD-10: C00-D09). Here preliminary total health care expenditures in 2011 were 288,572

million CZK; of these, health insurance companies covered 217,653 million, with 19,217 million per one cancer treatment. Between 1990 and

2011, the total health expenditures increased by 257,534 million CZK, accounting for 7.58 % of the gross domestic product. In 2010 the General

Health Insurance Company paid on average 19,030 CZK for the treatment of one cancer case, with the highest expenditures for neoplasms of

the lymphoid and haemotopoietic tissues, brain and central nervous system, digestive organs, oral cavity and pharynx, and respiratory organs.

The global economic performance cannot provide enough resources for public health care. The Czech public debt exceeded 1,680 billion CZK

at the time this article was written. Although out-of-pocket money paid by cancer patients for treatment is growing, the continuing public

indebtedness is likely to increase debts of hospitals and health insurance companies. The estimated growing numbers of cancer patients and

related costs of their treatment call for consistent cancer prevention measures and effective allocation and utilization of health care resources.

Keywords: malignant neoplasms, expected numbers, economic indicators in the population and health care

Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Geryk E, Koška P, Horváth T, Živec V. Cancers, health and economy - parts of Pandora´s box? Onkologie. 2013;7(1):40-47.
Download citation

References

  1. WHO. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: Health Organization; 2009.
  2. CSDH. Closing the gap in a generation: health equity through action on the social determinants of health. Final report of the commission on social determinants of health. Geneva: WHO; 2008.
  3. IARC. Cancer incidence, mortality and prevalence worldwide in 2008, Globocan 2008, Lyon: Internat Agency Res Canc, http://globocan.iarc.fr/.
  4. IARC. Cancer Incidence in Five Continents. Lyon: Internat Agency Res Canc 2011; 2011; Vol. X, http://ci5.iarc.fr/.
  5. IARC. Automated Childhood Cancer Information System, Lyon: Internat Agency Res Canc, http://accis.iarc.fr/about/index.php.
  6. IARC. International Incidence of Childhood Cancer. Lyon: Internat Agency Res Canc 2011; Vol. 3, http://iicc.iarc.fr/.
  7. IARC. European Cancer Observatory. Lyon: Internat Agency Res Canc, http://eu-cancer.iarc.fr/.
  8. Engholm G, Ferlay J, Christensen N, et al. NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010; 49(5): 725-736. Go to original source... Go to PubMed...
  9. Štampach R, Geryk E. Health statistics in international databases and their cartographic visualization. Quaestiones geographicae, Poznań: Uniwersytet A. Mickiewicza, 2012; 31(3): 77-88. Go to original source...
  10. Dvacet pět let Čsl. spolku pro potírání a zkoumání zhoubných nádorů v Praze. Praha, 1930.
  11. Weiss J. Příspěvek ke statistikám o přibývání rakoviny. Prakt. Lék. 1933; 22: 617.
  12. Nečas J. Boj proti rakovině v naší vlasti. Čas Lék Čes 1947; 135: 957.
  13. Pantoflíček J, Boháč A, et al. Atlas Republiky Československé. Praha: Česká akademie věd a umění, 1935; (18): mapa M22-2d.
  14. Žáček A. Rakovina v ČSR jako zdravotně sociální problém. Analysa úmrtnosti. Brno: Spisy lékařské fakulty MO a PU, 1951; 24(3): 1-130.
  15. ÚZIS. Novotvary 2009 ČR. Praha: ÚZIS ČR, 2012: 264, Zdravotnická statistika, ISBN 978-80-7280-975-2, ediční řada za roky 1959-2009.
  16. Geryk E, Kolcová V, Maršík V, et al. Atlas zhoubných nádorů v ČR. Brno: Kartuziánské nakl. 1995: 85.
  17. Konečný M, Geryk E, Kubíček P, Dítě P, Koška P, et al. Prevalence nádorů v České republice, 1989-2005-2015. Brno: PřF MU, 2008: 69.
  18. Dušek L, Bartoňková H, et al. Czech cancer care in numbers. Praha: Grada, 2009: 471.
  19. http://www.alfafinance.cz/statni-dluh.
  20. IARC. Globocan 2008, Lyon: Internat Agency Res Canc, http://globocan.iarc.fr/.
  21. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010; 127(12): 2893-2917. Go to original source... Go to PubMed...
  22. ÚZIS. Ekonomické informace ve zdravotnictví 2011. Zdravotnická statistika ČR, 2012: 132.
  23. VZP. Ročenka všeobecné zdravotní pojišťovny ČR za rok 2010, Praha: VZP, 2011: 57-73. www.vzp.cz.
  24. http://www.cancer.org./.
  25. http://www.nih.gov/.
  26. NIH. Cost of Illness Report to the U.S. Congress, National Health Care Expenditures Projections, 2003-2013, National Institute of Health, 2005.
  27. http://www.nhlbi.nih.gov/o/factpdf.htm.
  28. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annual Review of Public Health in 2001. 2004; 22: 91-113. Go to original source... Go to PubMed...
  29. http://www.cms.gov/statistics/nhe/projections-2003/proj2003.pdf.
  30. ČOS. http://www.lincos.cz.
  31. Heger L. Přerozdělování pojistného potřebuje změnu. Infoservis 2011; 1(2): 1-3.
  32. http://www.mzcr.cz/Unie/obsah/aktuality_1152_8.html, Věstník č. 3/2012, 4/2012 a 8/2012, MZ ČR, 2012.
  33. Billroth CAT, et al. Die allgemeine chirurgische patologie und terapie. Berlin: Reimer G 1989: 908.
  34. Curtis RE, Freedman M, Ron E, Ries LAG, el al. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. Bethesda: Nat Canc Inst, NIH Publ. No. 05-5302, 2006: 492.
  35. Geryk E, Dítě P, Kozel J, et al. Nádorové multiplicity u české populace. Čas Lék Čes 2011; 149(4): 178-183.
  36. Geryk E, Dítě P, Trna J, et al. Klinická stadia u nemocných s vícečetnými novotvary. Onkologie 2010; 4(6): 357-361.
  37. http://www.healingnews.com/.
  38. Bleyer AH, Welch G. Effect of three decades of screening mammography on breast-cancer incidence, N Engl J Med 2012; 367: 1998-2005. Go to original source... Go to PubMed...
  39. http://www.nejm.org/doi/full/10.1056/NEJMoa1206809?query=featured_hom.
  40. Tyleček J. Fiskální útes v USA. www.finance.cz.
  41. Sikorski R. Projev ministra zahraničních věcí Polska, Blenheim Palace, 21.9. 2012 EU Documents, Blenheim Palace Speech, 2012.
  42. ÖGPP. Der Armut in EU. Österreichischen Gesellschaft für Politikberatung und Politikentwicklung, 2012.
  43. Rada pro zdraví a životní prostředí. Akční plán zdraví a životního prostředí ČR. Jednání vády ČR č.j. 1352/2011, ze dne 4. 1. 2012.
  44. Fried LP, Bentley ME, Buekens P, et al. Global health is public health. Lancet 2010; 375: 535-537. Go to original source... Go to PubMed...
  45. Deleuze G, Guattari F. A thousand plateaus: capitalism and schizophrenia. 5 edition. London, N. York: Continuum; 2004.
  46. Stuckler D, Basu S. The International Monetary Fund's effects on global health: before and after the 2008 financial crisis. Int J Health Serv 2009; 39: 771-781. Go to original source... Go to PubMed...
  47. Reich MR, Takemi K. G8 and strengthening of health systems: follow-up to the Tokyo summit. Lancet 2009; 373: 508-515. Go to original source... Go to PubMed...
  48. Banerjee A, Hollis A, Pogge T. The health impact fund: incentives for improving access to medicines. Lancet 2010; 375: 166-169. Go to original source... Go to PubMed...
  49. Cornwall A, Brock K. What do buzzwords do for development policy? A critical look at, ,participation, empowerment and poverty reduction". Third Quarterly 2005; 26: 1043-1060. Go to original source...
  50. Martin G, Bird P, Crichton C. Global health: where are our priorities? Br Med Bulletin 2009; 91: 23-28. Go to original source... Go to PubMed...
  51. Oslo Ministerial Declaration - global health: a pressing foreign policy issue of our time. Lancet 2007; 369: 1373-1378. Go to original source... Go to PubMed...
  52. Labonte R, Gagnon M. Framing health and foreign policy: lessons for global health diplomacy. Globalization and Health 2010; 6: 14. Go to original source... Go to PubMed...
  53. Erikson SL. Getting political: fighting for global health. Lancet 2008; 371: 1229-1230. Go to original source... Go to PubMed...
  54. WHO Maximizing Positive Synergies Collaborative Group: An assessment of interactions between global health initiatives and country health systems. The Lancet 2009; 373: 2137-2169. Go to original source... Go to PubMed...
  55. Backman G, Hunt P, Khosla R, et al. Health systems and the right to health: an assessment of 194 countries. Lancet 2008; 372: 2047-2085. Go to original source... Go to PubMed...
  56. The Economist. To have, not to hold: the rise of the new philanthropists. The Economist 2006.
  57. McCoy D, Kembhavi G, Patel J, Luintel A. The Bill & Melinda Gates Foundation's grant-making programme for global health. The Lancet 2009; 373: 1645-1653. Go to original source... Go to PubMed...
  58. Birn AE. Gates's grandest challenge: transcending technology as public health ideology. The Lancet 2005; 366: 514-519. Go to original source... Go to PubMed...
  59. Kašparů M. Čas kyvadla. http://www.norbertinum.cz.
  60. Zieleniec J, et al. Československo na rozcestí. Praha: Ekonomický Ústav ČSAV, 1898.
  61. Svejnar J. A framework for the economic transformation of the Czechoslovakia. Pittsburgh: University of Pittsburgh, PhanEcon 1989; 5(52): 1-18.
  62. Švejnar J. Strategie ekonomické přeměny Československa. Praha: Lidové Noviny, 1990: 48.
  63. Pavelek P. Strategie financování a řízení státního dluhu České republiky na rok 2011. Praha: MF ČR, Odb. řízení státního dluhu a finančního majetku, 2010: 41, www.mfcr.cz/statnidluh.
  64. Tangka FK, Trogdon JG, Richardson LC, et al. Cancer treatment cost in the United States: has the burden shifted over time? Cancer 2010; 14: 3477-3484. Go to original source... Go to PubMed...
  65. Soffritti M, Belpoggi F, Manservigi M, et al. Aspartame administered in feed, beginning prenatally through life span, induces cancers of the liver and lung in male Swiss mice. Am J Ind Med 2010; 53: 1197-1206. Go to original source... Go to PubMed...
  66. Strunecká A. Patočka J. Doba jedová. 2012: 368.
  67. Olney JW, Farber NB, Spitznagel, et al. Increasing brain tumor rates: is there a link to aspartame? J Neuropatol Exp Neurol 1996; 55(11): 1115-1123. Go to original source... Go to PubMed...
  68. http://www.vitalia.cz/galerie/e-920-l-cystein/.
  69. Grygar J. Nekonečný příběh konců světa - Mayské proroctví o konci světa 2012, pravda či fikce? www.sisyfos.cz.
  70. Engliš K. Soustava národního hospodářství - věda o pořádku, ve kterém jednotlivci a národové pečují o udržení a zlepšení života. Praha: Melantrich, 1938: 891.
  71. Caldwellová T. A pillar of iron. http://message.snopes.com/showthread.php?t=28532.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.